An experimental Novartis drug designed to treat a genetic cause of heart disease failed to reduce deaths and non-fatal heart attacks, dashing hopes for the first of several such drugs in ...

Jayakrishna Ambati, MD, discusses phase 2 K8 results in GA, its inflammasome mechanism, and dosing designed for convenience.

Novartis said testing found evidence of vector DNA integration in two children who had previously received its Zolgensma gene therapy for spinal muscular atrophy. In an emailed statement to ...

Nine reports of tumors in children treated with Novartis' spinal muscular atrophy (SMA) gene therapy Zolgensma raise new ...

A multi-center study of 1312 subjects localized a common episodic memory-associated impaired network in mild cognitive ...

A meta-analysis of 16 preclinical studies found that interventions for acquired muscle atrophy significantly improved grip ...

ForTra’s GMP funding helps to bridge the funding gap and supports the development of the first in-human clinical trials of gene and cell therapies ...

Danny Donnelly MLA said: “Every baby born in Northern Ireland should have the same opportunity for an early diagnosis of ...

I am an acupuncturist and nurse who loves cats🐱It has been 21 years since I developed a brain disease, and while I still ...

Manitobans living with spinal muscular atrophy (SMA) could gain access to publicly funded treatments under revised national recommendations accepted by the provincial government. Health, Seniors and ...

OliX Pharmaceuticals filed a US IND for OLX301A, a siRNA drug targeting MyD88, the retinal inflammation amplifier Syfovre and Izervay cannot silence. OLX301A now enters the FDA 30-day review window; ...

🚨 One Nation volunteer bashed with baseball bat in front of his family after confronting sign vandal The alleged attack is understood to have begun when a 14-year-old boy started damaging One Nation ...